[以色列幽门螺杆菌对抗生素的耐药性：过去与现在]

[RESISTANCE OF HELICOBACTER PYLORI TO ANTIBIOTICS IN ISRAEL: PAST VS PRESENT].

作者信息

Peretz Avi, Paritsky Maya, Brodsky Diana, Pastukh Nina, On Avi

机构信息

Clinical Microbiology Laboratory, Baruch Padeh Medical Center, Poriya, affiliated to the Faculty of Medicine, Bar Ilan University, Galilee, Israel.

Gastrointestinal Unit, Baruch Padeh Medical Center, Poriya, affiliated to the Faculty of Medicine, Bar Ilan University, Galilee, Israel.

出版信息

Harefuah. 2017 Oct;156(10):642-644.

PMID:29072383

Abstract

Helicobacter Pylori (H. Pylori) is a spiral shaped Gram-negative bacterium which is known to cause chronic gastric inflammation (gastritis) that could develop into a gastric or duodenal ulcer. The standard first line therapy for H. Pylori infection is a 7-14 days period of "triple therapy" consisting of proton pump inhibitors (PPI) and the antibiotics clarithromycin and amoxicillin or metronidazole. Recently there has been an increase in H. Pylori resistance to antibiotic treatment. Throughout the years 1999, 2002, 2010, 2013 and 2014 studies have been conducted in Israel that examined H. Pylori resistance rates for commonly used antibiotics. These studies included 40-138 participants who were diagnosed with infection caused by H. Pylori. Based on information derived from these studies, there is a clear increase in H. Pylori resistance to antibiotics, particularly to tetracycline, amoxicillin and clarithromycin.

摘要

幽门螺杆菌是一种螺旋形革兰氏阴性菌，已知可引起慢性胃炎症（胃炎），进而可能发展成胃溃疡或十二指肠溃疡。幽门螺杆菌感染的标准一线治疗方案是进行为期7至14天的“三联疗法”，包括质子泵抑制剂（PPI）以及抗生素克拉霉素和阿莫西林或甲硝唑。近年来，幽门螺杆菌对抗生素治疗的耐药性有所增加。在1999年、2002年、2010年、2013年和2014年期间，以色列开展了多项研究，检测常用抗生素对幽门螺杆菌的耐药率。这些研究纳入了40至138名被诊断为幽门螺杆菌感染的参与者。根据这些研究得出的信息，幽门螺杆菌对抗生素的耐药性明显增加，尤其是对四环素、阿莫西林和克拉霉素。